Breaking Finance News

A statement released earlier today by William Blair about Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) bumps the target price to $26.00

Indicating a possible upside of 1.26%, William Blair raised the price target of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to $26.

Boasting a price of $11.49, Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) traded 5.27% lower on the day. With the last stock price close up 16.17% relative to the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same period. Spring Bank Pharmaceuticals Inc has recorded a 50-day moving average of $11.17 and two hundred day average of $10.52. Volume of trade was was up over the average, with 17,396 shares of SBPH changing hands over the typical 7,017 shares.

Recent Performance Graph:

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH)

With a market capitalization of $0.0, Spring Bank Pharmaceuticals Inc has a PE of 0 with a 52 week low of $7.62 and a 52 week high of $13.25.

More About Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH)

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. Its SMNH compounds are small segments of nucleic acids that the Company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Its product, SB 9200 for the chronic hepatitis B indication or therapeutic area is under Phase II development stage; SB 9200 for respiratory syncytial virus indication or therapeutic area is under Phase II development stage; SB 9200 for the hepatitis C virus indication or therapeutic area has completed Phase I development stage, and and SB 9200 for the human immunodeficiency virus latency and hepatitis delta virus indication or therapeutic area are under research stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.